Chester County News and Community Website
RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical trials. The event …
Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled …
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has scheduled a conference call and webinar on Monday, March 10, 2025, at 8:00 a.m. ET to present topline results from its …
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported its financial results for the fourth quarter and full year ending December 31, 2024, while sharing significant updates on the development of …
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The study is evaluating the efficacy and safety of lorundrostat, …
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 2 clinical trial …
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has released its financial results for the third quarter ending September 30, 2024, alongside key updates on its clinical trials. The company …
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More